Alembic Pharmaceuticals has informed that the Company has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit at API-II Facilty at Panelav for its 8 APIs. The inspection was conducted from 16th September, 2024 to 20th September, 2024.
The above information is a part of company’s filings submitted to BSE.